James Goodman

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial

J. Graggaber, G. Boehmer, G. Koduri, 2023, The Lancet. Respiratory medicine.